for prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction or when administered (in conjunction with warfarin) as inpatient treatment of acute DVT with or ...

All of the newer anticoagulants currently available for the management of VTE and ACS have FDA-approved labeling for use in patients with mild-to-moderate renal impairment. Prescribing information ...

A phase IIa trial has demonstrated that a structural analogue of warfarin is safe, tolerable, and efficacious. Investigators believe that this new anticoagulant, named tecarfarin, will be ...

Daiichi Sankyo's new anticoagulant Lixiana should be available on the NHS in England and Wales for the treatment and prevention of recurrent blood clots in the legs and lungs, according to NICE.

US biotech Regeneron Pharmaceuticals has announced positive Phase II results for two novel monoclonal antibodies targeting ...

Keywords /Health and medicine/Clinical medicine/Medical treatments/Drug therapy/Medications/ Anticoagulants /Applied sciences and engineering/Risk management/ Risk reduction /Health and medicine ...

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, ...

FRIDAY, Dec. 6, 2024 (HealthDay News) -- Noninferiority of reduced- versus full-dose anticoagulants cannot be proven in ...

Antiphospholipid antibodies, including lupus anticoagulant assays run on automated coagulation platforms are one part of the panel of tests recommended to screen and diagnose aPS. As a member of the ...

Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagulant.